Increased osteoclast activity is associated with aggressiveness of osteosarcoma

International Journal of Oncology

Volumn 33, Issue 6, 2008, Pages 1231-1238

  Avnet, Sofia ^a   Longhi, Alessandra ^a   Salerno, Manuela ^a   Halleen, Jussi M ^b   Perut, Francesca ^a   Granchi, Donatella ^a   Ferrari, Stefano ^a   Bertoni, Franco ^a   Giunti, Armando ^a,c   Baldini, Nicola ^a,c  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b Pharmatest Services Ltd   (Finland)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bone turnover markers; Metastases; Osteoclast; Osteosarcoma; Tumor aggressiveness

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; GELATINASE B; ISOPROTEIN; TARTRATE RESISTANT ACID PHOSPHATASE ISOFORM 5B; UNCLASSIFIED DRUG; ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN; CATHEPSIN K; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; COLONY STIMULATING FACTOR 1; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; ISOENZYME; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RECEPTOR 1; PARATHYROID HORMONE RELATED PROTEIN; PEPTIDE; PTHR1 PROTEIN, HUMAN; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFSF11 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER SURGERY; CELL ACTIVITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MALE; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; BLOOD; BONE TUMOR; CASE CONTROL STUDY; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; TIME; TUMOR CELL LINE;

ACID PHOSPHATASE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE NEOPLASMS; BONE RESORPTION; CASE-CONTROL STUDIES; CATHEPSINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; COLLAGEN TYPE I; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; ISOENZYMES; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; OSTEOCLASTS; OSTEOSARCOMA; PARATHYROID HORMONE-RELATED PROTEIN; PEPTIDES; RANK LIGAND; RECEPTOR, PARATHYROID HORMONE, TYPE 1; RNA, MESSENGER; TIME FACTORS; YOUNG ADULT;

EID: 59049105619     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000113     Document Type: Article

References (46)

1. Pringle JA: Bone-forming neoplasms arising within bone. In: Pathology of Bone and Joint Neoplasms. Helliwell TR (ed). WB Saunders Company, Philadelphia, pp172-189, 1999.
2. Campanacci M: Bone and Soft Tissue Tumors. 2nd edition, Springer, Wien, pp463-515, 1999.
3. Link MP, Goorin AM, Miser AW, et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-1606, 1986.
4. Baldini N, Scotlandi K, Barbanti-Brodano G, et al: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380-1385, 1995.
5. Scotlandi K, Baldini N, Oliviero M, et al: Expression of Met/ hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 149: 1209-1219, 1996.
6. Patane S, Avnet S, Coltella N, et al: MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 66: 4750-4757, 2006.
7. Bacci G, Forni C, Longhi A, et al: Local recurrence and local control of non-metastatic osteosarcoma of the extremities: A 27-year experience in a single institution. J Surg Oncol 96: 118-123, 2007.
8. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K and Ishiguro N: Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 28: 33-42, 2006.
9. Biornland K, Flatmark K, Petterson S, Aaasen AO, Fodstad O, and Maelandsmo GM: Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 127: 151-156, 2005.
10. Ferrari C, Benassi S, Ponticelli F, et al: Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcoma: findings in 42 patients followed for 1-16 years. Acta Orthop Scand 75: 487-491, 2004.
11. Harvey HA and Cream LR: Biology of bone metastases: causes and consequences. Clin Breast Cancer 7: S7-S13, 2007.
12. Bathurst N, Sanerkin N and Watt I: Osteoclast-rich osteosarcoma. Br J Radiol 59: 667-673, 1986.
13. Kinpara K, Mogi M, Kuzushima M and Togari A: Osteoclast differentiation factor in human osteosarcoma cell line. J Immunoassay 21: 327-340, 2000.
14. Miyamoto N, Higuchi Y, Mori K, et al: Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol 2: 25-38, 2002.
15. Bacci G, Ferrari S, Mercuri M, et al: Neoadjuvant chemotherapy for extremity osteosarcoma-preliminary results of the Rizzoli's 4th study. Acta Oncol 37: 41-48, 1998.
16. Ferracini R, Di Renzo MF, Scotlandi K, et al: The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit. Oncogene 10: 739-749, 1995.
17. Vääräniemi J, Halleen JM, Kaarlonen K, et al: Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res 19: 1432-1440, 2004.
18. Tezuka K, Nemoto K, Tezuka Y, et al: Identification of matrix metalloproteinase 9 in rabbit osteoclasts. J Biol Chem 269: 15006-15009, 1994.
19. Hojilla CV, Mohammed FF and Khokha R: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 89: 1817-1821, 2003.
20. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS and Lopez-Otin C: Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 532: 91-107, 2003.
21. Himelstein BP, Asada N, Carlton MR and Collins MH: Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol 31: 471-474, 1998.
22. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG and Taylor S: Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumor cells. J Bone Joint Surg Br 84: 706-711, 2002.
23. Thomas RJ, Guise TA, Yin JJ, et al: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458, 1999.
24. Deng X, Tannehill-Gregg SH, Nadella MV, et al: Parathyroid hormone-related protein and ezrin are up-regulated in human lung cancer bone metastases. Clin Exp Metastasis 24: 107-119, 2007.
25. Yang R, Hoang BH, Kubo T, et al: Over-expression of parathyroid hormone type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 121: 943-954, 2007.
26. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664, 2004.
27. Demers LM, Costa L and Lipton A: Biochemical markers and skeletal metastases. Cancer 88: 2919-2926, 2000.
28. Chao TY, Yu JC, Ku CH, et al: Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clin Cancer Res 11: 544-550, 2005.
29. Costa L, Demers LM, Gouveia-Oliveira A, et al: Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20: 850-856, 2002.
30. Apone S, Lee MY and Eyre DR: Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 21: 129-136, 1997.
31. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR and Eyre DR: A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7: 1251-1258, 1992.
32. Mook OR, Frederiks WM and Van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705: 69-89, 2004.
33. Kanayama H: Matrix metalloproteinases and bladder cancer. J Med Invest 48: 31-43, 2001.
34. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ and Vaananen HK: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15: 1337-1345, 2000.
35. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ and Väänänen HK: Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47: 597-600, 2001.
36. Alatalo SL, Halleen JM, Hentunen TA, Mönkkönen J and Väänänen HK: Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 46: 1751-1754, 2000.
37. Chu P, Chao TY, Lin YF, Jankila AJ and Yam LT: Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodyalisis. Am J Kidney Dis 41: 1052-1059, 2003.
38. Mintz MB, Soers R, Brown KM, et al: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65: 1748-1754, 2005.
39. Kubista B, Trieb K, Sevelda F, et al: Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 24: 1145-1152, 2006.
40. Heymann D, Ory B, Blanhard F, et al: Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37: 74-86, 2005.
41. Lamoureux F, Richard P, Wittrant Y, et al: Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the viciuos cycle between tumor cell proliferation and bone resorption. Cancer Res 67: 7308-7318, 2007.
42. Chung YC, Ku CH, Chao TY, et al: Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomarkers Prev 15: 424-428, 2006.
43. Coussens LM and Wrb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
44. Condeelis J and Pollard JW: Marcophages. Obligate partners for tumor cell migration, invasion, and metastases. Cell 124: 263-266, 2006.
45. Holzer G, Krepler P, Koschat MA, Grampp S, Dominkus M and Kotz R: Bone mineral density in long-term survivors of highly malignant osteosarcoma. J Bone Joint Surg [Br] 85-b: 231-237, 2003.
46. Stanisavijevic S and Babcock A: Fractures in children treated with methotrexate for leukemia. Clin Orthop 125: 139-144, 1977.